Posted by Michael Wonder on 18 Jun 2021
Health Canada grants marketing authorisation for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people ages 12 and older who have at least one F508del mutation
18 June 2021 - Approximately 1,100 F/MF patients now eligible for a CFTR modulator to treat the underlying cause of their disease.
Vertex Pharmaceuticals today announced Health Canada has granted marketing authorisation for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene, the most common cystic fibrosis causing mutation.
With this approval, for the first time, approximately 1,100 eligible patients with cystic fibrosis ages 12 years and older who have at least one F508del mutation have a medicine that targets the underlying cause of their cystic fibrosis.
